Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 15/20 | 0.82 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.82 |
| ▸ | PDE2A | O00408 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14299976 | 1.00 | PTGER4 (0.82) | PTGER4PTGER2PDE2AALDH1A1LMNA | |
| SCHEMBL2353056 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL13655944 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL4090963 | 0.89 | PTGER4 (0.98) | PTGER4PTGER2 | |
| SCHEMBL4090960 | 0.89 | PTGER4 (0.82) | PTGER4PTGER2PDE2A | |
| SCHEMBL2353326 | 0.87 | PTGER4 (1.00) | PTGER4PTGER2PDE2A | |
| SCHEMBL14299809 | 0.87 | PTGER4 (1.00) | PTGER4PTGER2PDE2A | |
| SCHEMBL28801438 | 0.86 | PTGER4 (0.78) | PTGER4PTGER2PDE2AALDH1A1LMNA | |
| SCHEMBL13649212 | 0.86 | PTGER4 (0.60) | PTGER4PTGER2PDE2AALDH1A1 | |
| SCHEMBL14299923 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2PDE2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2538978-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | claimed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | claimed |
| CN-102770159-A | Use of EP-4 receptor antagonists for the treatment of IL-23 mediated diseases | RAQUALIA PHARMA INC | 2012-11-07 | — | — | CN | claimed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | claimed |
| CN-107693518-A | Purposes of the receptor antagonists of EP 4 in treatment IL 23 is disease mediated | 株式会社ＡｓｋＡｔ | 2018-02-16 | — | — | CN | disclosed |
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| EP-2538978-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | disclosed |
| CN-102770159-A | Use of EP-4 receptor antagonists for the treatment of IL-23 mediated diseases | RAQUALIA PHARMA INC | 2012-11-07 | — | — | CN | disclosed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | PTGER4, PTGER3, IL23R | PTGER4 1/4885PTGER2 6/4885PDE2A 1942/4885 |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PDE2A 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.